News | November 10, 2021
Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Divi's Laboratories Limited has reported consolidated financial results for the period ended September 30, 2021.
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The transplant procedure was completed in under two hours
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated
